Related by context. All words. (Click for frequent words.) 72 lorvotuzumab mertansine 72 huN# DM1 71 ganetespib 70 AP# [003] 70 Phase Ib study 70 CR# vcMMAE 70 pomalidomide 70 alvespimycin 69 axitinib 69 PXD# 69 T DM1 69 tanespimycin 69 enzastaurin 69 Phase Ib 69 SAR# [004] 68 HER2 positive metastatic breast 68 Traficet EN 68 huC# DM4 68 relapsed refractory multiple myeloma 68 INCB# [002] 68 bendamustine 67 CoFactor 67 carfilzomib 67 OncoVEX GM CSF 67 HGS ETR1 67 glufosfamide 67 PEG SN# 67 ofatumumab 67 heavily pretreated 67 phase IIb clinical 67 refractory CLL 67 Cotara 67 IMA# 66 adecatumumab 66 Carfilzomib 66 elotuzumab 66 nab paclitaxel 66 IIa trial 66 Phase IIIb clinical 66 HuMax CD4 66 phase IIa clinical 66 obatoclax 66 PSMA ADC 66 pertuzumab 66 Phase 2b study 66 HuMax EGFr 66 XmAb# 66 Azedra 66 Phase Ib clinical 66 olaparib 66 pralatrexate 66 dose escalation trial 66 mapatumumab 66 elacytarabine 66 INCB# [001] 66 perifosine 66 metastatic renal cell carcinoma 66 Amrubicin 65 Phase 2b trial 65 Bezielle 65 EOquin 65 thymalfasin 65 dose cohorts 65 mertansine 65 antitumor activity 65 Phase IIa clinical 65 decitabine 65 YONDELIS 65 picoplatin 65 EOquin TM 65 FOLOTYN 65 BAY #-# 65 anti leukemic 65 crizotinib PF # 65 phase IIb 65 AEG# 65 Phase 2a trial 65 forodesine 65 dasatinib 65 Alocrest 65 Phase 2b clinical 65 refractory multiple myeloma 65 mRCC 65 orally bioavailable 65 IMC A# 65 XL# [003] 65 romidepsin 65 TELCYTA 65 vandetanib 65 oral ridaforolimus 65 LY# [003] 65 registrational 64 AQ4N 64 biologic therapy 64 CCX# 64 Phase 1b 64 relapsed refractory 64 Taxotere ® 64 trabectedin 64 Azixa 64 tamibarotene 64 histone deacetylase HDAC inhibitor 64 JAK inhibitor 64 CYC# 64 Sym# 64 Marqibo 64 Cloretazine R VNP#M 64 Panzem R NCD 64 Archexin 64 investigational compound 64 satraplatin 64 PEP# [003] 64 eniluracil 64 platinum refractory 64 relapsed multiple myeloma 64 oral prodrug 64 Zolinza 64 dose cohort 64 eltrombopag 64 MabCampath 64 lumiliximab 64 metastatic RCC 64 veltuzumab 64 phase Ib 64 Allovectin 7 ® 64 ixabepilone 64 Perifosine 64 tolerated dose MTD 64 EndoTAG TM -1 64 NP2 Enkephalin 64 Aplidin 64 Phase Ib II 64 GAP #B# 64 imatinib Gleevec ® 64 INC# 64 Tamibarotene 64 Alpharadin 64 neratinib 64 lintuzumab 64 GLP toxicology studies 63 subcutaneous formulation 63 OXi# 63 MAGE A3 ASCI 63 metastatic colorectal cancer 63 heavily pretreated patients 63 HspE7 63 sapacitabine 63 indolent NHL 63 L BLP# 63 HuMax CD# 63 registrational trial 63 Irinotecan 63 Voreloxin 63 PRTX 63 superficial bladder cancer 63 bortezomib 63 ZYBRESTAT 63 PEG PAL 63 Pemetrexed 63 Fludara 63 Telintra 63 zanolimumab 63 liver metastases 63 trastuzumab DM1 T DM1 63 cell lymphoma CTCL 63 seliciclib 63 advanced NSCLC 63 trastuzumab DM1 63 carboplatin paclitaxel 63 docetaxel chemotherapy 63 ponatinib 63 RDEA# 63 PF # [001] 63 Phase 1b trial 63 vinorelbine 63 PRT# 63 chronic lymphocytic leukemia CLL 63 Dacogen injection 63 phase IIb trial 63 CA4P 63 MGCD# [001] 63 entinostat 63 Ceflatonin 63 #D#C# 63 evaluable patients 63 Golimumab 63 pharmacokinetics PK 63 HGS# 63 blinatumomab 63 Virulizin ® 63 TG# [001] 63 leukemia CLL 63 OncoVEX 63 hA# 63 Trastuzumab 63 DAVANAT 63 hematological cancers 63 velafermin 63 Phase 1b clinical 63 teriflunomide 63 Bortezomib 63 Cloretazine ® 63 ongoing Phase 1b 63 afatinib 63 Phase IIb trial 63 OMAPRO 63 talactoferrin 63 chlorambucil 63 MORAb 63 ARIKACE 63 Neuvenge 63 abiraterone acetate 63 Phase IIa trial 63 Phase 1a 63 vidofludimus 63 tolerability 63 azacitidine 63 amrubicin 63 GW# [003] 63 CANCIDAS 63 confirmatory Phase III 63 Ceplene/IL-2 63 FavId 63 subcutaneously administered 63 receptor tyrosine kinase inhibitor 63 Telatinib 63 cilengitide 62 dose escalation 62 viral kinetics 62 metastatic melanoma 62 Phase III clinical 62 darinaparsin 62 galiximab 62 relapsed SCLC 62 nilotinib 62 vismodegib 62 recurrent GBM 62 sorafenib Nexavar 62 cannabinor 62 Genasense ® 62 pan HDAC inhibitor 62 relapsed MCL 62 ONCONASE 62 anticancer compound 62 temsirolimus 62 taxane 62 Aflibercept 62 pharmacodynamic PD 62 Exherin TM 62 VEGF Trap 62 milatuzumab 62 CYT# 62 metastatic CRC 62 ASA# 62 tocilizumab 62 Hycamtin 62 ZACTIMA 62 CD# antibody [001] 62 CEQ# 62 assessing T DM1 62 DermaVir Patch 62 ADVEXIN 62 standard chemotherapy regimen 62 FTY# 62 aflibercept 62 proteasome inhibitor 62 IRX 2 62 Pixantrone 62 SCCHN 62 Allovectin 7 R 62 imetelstat 62 MOZOBIL 62 TOCOSOL Paclitaxel 62 phase IIa 62 dosing cohort 62 Phase IIb trials 62 sunitinib malate 62 neoadjuvant chemotherapy 62 viral kinetic 62 palifosfamide 62 GAMMAGARD 62 belinostat 62 MGd 62 rituximab 62 Doxil ® 62 Tesetaxel 62 CCR5 antagonist 62 Targretin 62 CBLC# 62 NSCLC 62 Pivotal Phase III 62 ELACYT 62 farletuzumab 62 daclizumab 62 novel anticancer 62 HCD# [002] 62 PEGylated interferon beta 1a 62 Reolysin 62 BiovaxID 62 rilonacept 62 pazopanib 62 mitomycin 62 #mg/m# [001] 62 recurrent NSCLC 62 vascular disrupting agent 62 OPAXIO 62 PROSTVAC TM 62 ZOLINZA 62 refractory AML 62 Clolar 62 Pralatrexate 62 trabedersen 62 lupus nephritis 62 erlotinib Tarceva ® 62 Tarceva TM 62 follicular NHL 62 gemcitabine carboplatin 62 Tyrima 62 MDV# 62 resminostat 62 dasatinib Sprycel ® 62 GRN#L 62 TYKERB 62 Kahalalide F 62 dose escalation study 62 Phase 2a 62 Phase IIa trials 62 GALNS 62 favorable pharmacokinetic profile 62 carboplatin 62 Phase #/#a 62 investigational humanized monoclonal antibody 62 humanized monoclonal antibody 61 valopicitabine 61 REOLYSIN ® 61 TELINTRA 61 mycophenolate mofetil 61 Allovectin 7 61 docetaxel 61 Telcyta 61 BRAF inhibitor 61 tesetaxel 61 pegylated liposomal doxorubicin 61 epratuzumab 61 Phase #b/#a clinical 61 Symadex 61 HRPC 61 APTIVUS r 61 Xanafide 61 custirsen 61 preclinically 61 ipilimumab 61 NVA# 61 Genasense 61 iclaprim 61 dosage regimens 61 fluoropyrimidine 61 abiraterone 61 radiation sensitizer 61 docetaxel Taxotere 61 liposomal formulation 61 tesmilifene 61 Velcade bortezomib 61 mCRC patients 61 vicriviroc 61 castration resistant prostate cancer 61 Cloretazine 61 sunitinib 61 PANVAC VF 61 Blinatumomab 61 Interferon alpha 61 CLORETAZINE TM VNP#M 61 Epratuzumab 61 solithromycin 61 PROMACTA 61 VELCADE melphalan 61 Enzastaurin 61 indibulin 61 pivotal Phase III 61 melphalan prednisone 61 Orazol 61 ATL# [001] 61 recurrent glioblastoma multiforme 61 elagolix 61 relapsing multiple sclerosis 61 iniparib 61 celgosivir 61 bevacizumab Avastin ® 61 T#I mutation 61 Imprime PGG 61 Restanza 61 docetaxel Taxotere R 61 depsipeptide 61 TREANDA 61 pharmacodynamic 61 polymerase inhibitor 61 R#/MEM # 61 randomized Phase III 61 Aplidin R 61 Satraplatin 61 LymphoStat B 61 ProLindac 61 GVAX 61 deforolimus 61 TACI Ig 61 methylnaltrexone 61 ALN RSV# 61 MEK inhibitor 61 SCH # 61 dose limiting toxicities 61 Phase 2a clinical 61 phase IIb study 61 dose escalation clinical 61 rindopepimut 61 MEK inhibitors 61 Quinamed 61 Triolex 61 voreloxin 61 relapsed ovarian cancer 61 rFIXFc 61 Ophena TM 61 INCB# [003] 61 dacarbazine 61 BRIM2 61 EDEMA3 61 CIMZIA ™ 61 relapsed MM 61 LUX Lung 61 cutaneous T cell 61 Herceptin trastuzumab 61 AMN# [001] 61 Ofatumumab 61 gefitinib 61 samalizumab 61 Amigal 61 RGB # 61 relapsing remitting multiple sclerosis 61 Proxinium TM 61 BRIM3 61 bavituximab 61 PEG Interferon lambda 61 randomized discontinuation trial 61 SinuNase 61 AZD# 61 pharmacokinetic PK 61 ALN VSP 61 Annamycin 61 cetuximab 61 Locteron 61 imatinib resistant 61 LEP ETU 61 APTIVUS 61 recurrent glioblastoma 61 Vicinium TM 61 leukemia AML 61 BAL# [002] 61 Phase IIa 61 sunitinib Sutent ® 61 Aptivus ® 60 AeroLEF TM 60 Nanobody 60 metastatic hormone refractory 60 mcg dose 60 glioblastoma multiforme GBM 60 colorectal liver metastases 60 low dose cytarabine 60 VELCADE 60 Arranon 60 tipranavir 60 Phase Ia 60 gemcitabine 60 Phase #b/#a 60 Pegasys ® 60 PDX pralatrexate 60 recurrent ovarian cancer 60 SUTENT 60 ritonavir boosted 60 antibody MAb 60 resistant ovarian cancer 60 CTCL 60 Pharmacokinetics PK 60 dasatinib Sprycel 60 metastatic renal cell 60 Phase III clinical trials 60 Erlotinib 60 HuLuc# 60 INGN 60 immunomodulator 60 APOPTONE 60 HQK 60 temozolomide 60 telaprevir dosed 60 Mylotarg 60 multicenter Phase 60 oritavancin 60 Phenoptin 60 systemic RNAi therapeutic 60 ENMD # 60 pradefovir 60 BEXXAR 60 ruxolitinib 60 Gleevec resistant 60 ChronVac C ® 60 phase 2a 60 Phase #/#a trial 60 Chemophase 60 gemcitabine Gemzar ® 60 Tarvacin 60 albinterferon alfa 2b 60 TroVax 60 perifosine KRX 60 TORISEL 60 rNAPc2 60 Leukine 60 abatacept 60 Valortim R 60 cangrelor 60 Hsp# Inhibitor 60 ocrelizumab 60 octreotide 60 DXL# 60 GRNVAC1 60 Aurexis 60 xenograft models 60 TRIOLEX 60 CINTREDEKIN BESUDOTOX 60 Stedivaze 60 Zerenex 60 baminercept 60 MyVax R 60 oblimersen 60 anti EGFR antibody 60 dose escalation Phase 60 dacetuzumab 60 patients evaluable 60 Advexin 60 Laquinimod 60 enfuvirtide 60 Plicera 60 ToGA 60 lapatinib 60 confirmatory Phase 3 60 Alzhemed TM 60 IND submission 60 trastuzumab Herceptin R 60 Gemcitabine 60 Telaprevir 60 Dapagliflozin 60 preclinical efficacy 60 posaconazole 60 riociguat 60 TG# [003] 60 alkylating agent 60 Vitaxin 60 dirucotide 60 Jevtana 60 angiogenesis inhibitor 60 Urocidin 60 INT# [002] 60 CHOP chemotherapy 60 clofarabine 60 HCV protease inhibitor 60 Phase IIb 60 ACZ# 60 anticancer agent 60 thalidomide Thalomid 60 evaluating Xcytrin 60 ThermoDox 60 elvucitabine 60 Vandetanib 60 AKT inhibitor 60 dose escalation phase 60 EGFR TKI 60 Fludarabine 60 trastuzumab Herceptin 60 Pertuzumab 60 tiapamil 60 Abiraterone acetate 60 Phase 2b 60 Onconase 60 solid tumors 60 Phase III 60 budesonide foam 60 omacetaxine mepesuccinate 60 limiting toxicity 60 ONTAK 60 cetuximab Erbitux 60 diabetic neuropathic pain 60 FOLOTYN ® 60 Phase IIb clinical trials 60 cediranib 60 prucalopride 60 Atiprimod 60 ILLUMINATE 60 bevirimat 60 HER2 positive breast cancer 60 ProSavin 60 KRN# 60 Triapine 60 DOXIL 60 BCX# 60 Tanespimycin 60 preclinical studies 60 bevacizumab 60 trastuzumab emtansine T DM1 60 telbivudine 60 ACTEMRA TM 60 Ocrelizumab 60 #I TM# 60 Phase IIb clinical 60 refractory Hodgkin lymphoma 60 OMP #M# 60 plasma kallikrein inhibitor 60 tubulin inhibitor 60 PNP inhibitor 60 PARP inhibitor 60 SNT MC# 60 lymphoma CTCL 60 paclitaxel Taxol ® 60 CUDC 60 HGS ETR2 60 PKC# 60 IMC #B 60 Phase 1a clinical 60 triphendiol 60 MGCD# [002] 60 docetaxel Taxotere ® 60 maraviroc 60 Response Evaluation Criteria 60 PI3K/Akt pathway inhibitor 60 evaluating tivozanib 60 Zybrestat 60 pharmacodynamic effects 60 Cytoxan 60 maribavir 59 REVLIMID 59 randomized controlled Phase 59 vascular disrupting agents 59 ANYARA 59 bevacizumab Avastin 59 ENMD 59 motesanib 59 initiate Phase 1b 59 Phase Ib clinical trials 59 Taxotere R 59 vorinostat 59 radezolid 59 LEUKINE 59 Vidofludimus 59 chemotherapeutic agent 59 ADXS# 59 ketolide antibiotic 59 randomized Phase 59 lapatinib Tykerb 59 Pimavanserin 59 NEUVENGE 59 surrogate endpoint 59 Corlux 59 nonclinical studies 59 ORENCIA ® 59 pegylated interferons 59 erlotinib 59 Alkeran 59 JAK inhibitors 59 PLK1 SNALP 59 satraplatin Phase 59 VQD 59 Fodosine 59 masitinib 59 PROSTVAC ® 59 medullary thyroid cancer 59 antiviral activity 59 NKTR 59 VNP#M 59 maximally tolerated dose 59 randomized Phase IIb 59 interferon beta 1a 59 Raptiva ® 59 plus dexamethasone 59 NEUGENE 59 Teysuno 59 systemic ALCL 59 regorafenib 59 Dasatinib 59 dosing regimens 59 midstage trials 59 trastuzumab 59 tigecycline 59 REMUNE R 59 blinded randomized placebo controlled 59 ISTODAX 59 Viramidine 59 subcutaneous PRO 59 Asentar 59 Reverset 59 gemcitabine cisplatin 59 velaglucerase alfa 59 telaprevir VX 59 dexpramipexole 59 mCRC 59 MKC# PP 59 torezolid phosphate 59 TroVax ® 59 chronic myeloid leukemia CML 59 zalutumumab 59 protease inhibitor PI 59 CAELYX 59 KRAS mutations occur 59 DEB# 59 XL# XL# XL# 59 Fx #A 59 IL# PE#QQR 59 refractory NSCLC 59 placebo controlled clinical 59 apremilast 59 telaprevir dosing 59 paclitaxel Taxol R 59 Melphalan 59 LHRH antagonist 59 vemurafenib 59 cetuximab Erbitux ® 59 leading oral taxane 59 adalimumab 59 VIDAZA 59 Natalizumab 59 refractory gout 59 RH1 59 brentuximab vedotin 59 seliciclib CYC# 59 Androxal TM 59 Gemzar ® 59 tivozanib 59 HSP# inhibitor 59 Rebif ® 59 pharmacokinetic PK study 59 dosing cohorts 59 panitumumab 59 pharmacodynamics PD 59 bortezomib Velcade 59 Daclizumab 59 liposomal doxorubicin 59 edoxaban 59 rALLy trial 59 pharmacokinetic profile 59 Phase III randomized controlled 59 pegfilgrastim 59 stage IIIB 59 Rituximab 59 Intravenous CP 59 mg/m2 cohort 59 Degarelix 59 monotherapy 59 Elagolix 59 metaglidasen 59 Hyphanox 59 Phase #b/#a trial 59 Bronchitol 59 pegylated interferon alpha 59 NEUMUNE 59 Torisel 59 brivaracetam 59 Phase III trials 59 OvaRex ® MAb 59 Debio 59 MT# MEDI 59 EVIZON 59 BIBW 59 linaclotide 59 pemetrexed 59 MAb 59 Treanda 59 PROCHYMAL 59 NGX# 59 HCV RESPOND 2 59 oral methylnaltrexone 59 Troxatyl 59 FOLFIRI 59 glatiramer acetate 59 EGS# 59 RhuDex ® 59 Removab 59 Kevetrin 59 Pazopanib 59 EZN 59 MAA submission 59 Exelixis XL# 59 metastatic sarcoma 59 pitavastatin 59 investigational pan BCR 59 Omacetaxine mepesuccinate 59 eribulin mesylate 59 delafloxacin 59 refractory CTCL 59 cytotoxic 59 mTOR inhibitors 59 Panzem 59 orally dosed 59 multiple myeloma MM 59 mitoxantrone 59 sorafenib tablets 59 AZILECT R 59 KNS # 59 sorafenib 59 tremelimumab 59 oral antiviral 59 Neulasta ® 59 TEMODAL 59 ELND# 59 targeted radiotherapeutic 59 Valortim 59 Serdaxin 59 Tarvacin TM 59 PDE4 inhibitor 59 calcineurin inhibitors 59 Aeroquin 59 BENLYSTA 59 brain metastases 59 pharmacokinetic PK profile 59 CCX# B 59 EFAPROXYN 59 FOLPI 59 alicaforsen enema 59 K ras mutations 59 abatacept Orencia 59 TriRima 59 humanized anti 59 ASONEP 59 Seliciclib 59 volociximab 59 GSK# [001] 59 preclinical 59 lintuzumab SGN 59 gastrointestinal stromal tumors GIST 59 teduglutide 59 Anticalin R 59 darinaparsin ZIO 59 cetuximab Erbitux R 59 CYT# potent vascular disrupting 59 TRISENOX 59 Topotecan 59 FOLFOX regimen 58 Randomized Phase 58 T#I [002] 58 ENDEAVOR IV 58 oral FTY# 58 DAVANAT R 58 pixantrone 58 recurrent glioma 58 mg/m2 dose 58 ozarelix 58 Darusentan 58 oral deforolimus 58 OHR/AVR# 58 complete remissions 58 Xcytrin 58 tafamidis 58 cintredekin besudotox 58 NXL# 58 Apoptone 58 ara C 58 sorafenib Nexavar ® 58 JAK2 inhibitors 58 epigenetic therapies 58 CTCE 58 nucleoside analog 58 generation purine nucleoside 58 Litx 58 velafermin belinostat 58 Alemtuzumab 58 romiplostim 58 Hsp# inhibitor 58 ON #.Na 58 isoform selective 58 BNC# 58 MIRCERA 58 investigational hepatitis C 58 ZEVALIN 58 PCK# 58 SUCCEED trial 58 AEZS 58 Vectibix 58 Capesaris 58 evaluating REVLIMID 58 entecavir 58 Phase IIIb 58 TOLAMBA 58 neoadjuvant 58 Diamyd ® 58 ceftaroline 58 ALN TTR 58 M Vax 58 HBeAg positive patients 58 cell malignancies 58 talabostat 58 Nexavar ® 58 Folotyn 58 AeroLEF 58 RG# [001] 58 ZK EPO 58 Anthim 58 Decitabine 58 DASISION 58 orBec 58 AzaSite Plus 58 EDEMA4 58 ocular formulation 58 plus gemcitabine 58 Amplimexon 58 CIMZIA TM 58 PS# [001] 58 Glufosfamide 58 Omnitarg 58 mg kg dose 58 Loramyc R 58 topotecan 58 Mipomersen 58 Fibrillex TM 58 PLX# 58 AVADO 58 DermaVir 58 Emselex 58 prostate cancer mCRPC 58 DCVax R Brain 58 MAbs 58 HDACi 58 Bevacizumab 58 ofatumumab HuMax CD# 58 Phase IIa clinical trials 58 Virulizin R 58 LBH# 58 IRESSA 58 PSN# [002] 58 tezampanel 58 advanced carcinoid 58 AVN# [001] 58 generation NNRTI 58 Afatinib 58 IMiD 58 BLA filing 58 LE SN# 58 antitumor 58 panitumumab Vectibix 58 follicular lymphomas 58 metastatic castration resistant 58 interferon beta 1b 58 ISIS # 58 Ceflatonin R 58 aclidinium 58 HER2 positive 58 Triapine R 58 immunotherapeutic agent 58 Solid Tumors 58 AVE# 58 canakinumab 58 Elotuzumab 58 Gleevec imatinib mesylate 58 placebo controlled clinical trials 58 HCV SPRINT 58 ADAGIO study 58 virus HCV protease inhibitor 58 Talabostat 58 MAP# 58 PI3K inhibitor 58 cariprazine 58 Sapacitabine 58 KRAS status 58 Maximum Tolerated Dose MTD 58 Actilon 58 Onco TCS 58 Panzem NCD 58 nucleoside reverse transcriptase inhibitor 58 FOLPI regimen 58 5 FU 58 ZEVALIN ® 58 rilpivirine 58 lymphoid malignancies 58 non squamous NSCLC 58 MAXY alpha 58 ustekinumab 58 Cimzia ® certolizumab pegol 58 Milatuzumab 58 omacetaxine 58 safety tolerability pharmacokinetic 58 IAP inhibitor 58 EGFR HER2 58 HERmark 58 Clavis Pharma 58 ribavirin RBV 58 omega interferon 58 EndoTAGTM 1 58 IAP inhibitors 58 diagnosed multiple myeloma 58 PEGylated Fab fragment 58 disease modifying 58 Valortim ® 58 gefitinib Iressa 58 Palifosfamide 58 cytotoxic agents 58 Dalbavancin